Agios Appoints David Scadden, M.D., to the Board of Directors
“Throughout Dr. Scadden’s career, he has made pioneering research achievements in hematology, and we are honored to welcome him to our board of directors,” said
Dr. Scadden is a hematologist/oncologist and an expert on the medical applications of stem cell biology with a particular emphasis on its use in the settings of cancer and AIDS. He has published over 300 scientific papers and book chapters, and his laboratory has made fundamental contributions in understanding the regulation of stem cell function. Dr. Scadden is the recipient of numerous honors including membership in the
“I’m delighted to join Agios’ board of directors and work together to achieve a shared vision of making a difference in the lives of people with cancer,” said Dr. Scadden. “I look forward to combining my expertise with Agios’ proven ability to translate internally discovered novel targets into precision medicines.”
Concurrent with the appointment of Dr. Scadden,
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the expected benefits of Dr. Scadden's service on the board of directors of Agios and the company's plans for growth and advancement of its programs. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "potential," "possible," "hope," "could," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs, including the risks described under the caption "Risk Factors" included in Agios’ public filings with the
Contacts Investors:Kendra Adams , 617-844-6407 Senior Director, Investor & Public Relations Kendra.Adams@agios.comRenee Leck , 617-649-8299 Senior Manager, Investor & Public Relations Renee.Leck@agios.com Media:Holly Manning , 617-844-6630 Associate Director, Corporate Communications Holly.Manning@agios.com